Vanucizumab

Modify Date: 2024-01-02 11:34:15

Vanucizumab structure	Common Name	Vanucizumab
	CAS Number	1448221-05-3	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Vanucizumab

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1].

Name	Vanucizumab

Description	Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
In Vivo	Vanucizumab (20mg /kg;i.p。每周1次;6周) 显示肿瘤生长抑制和诱导肿瘤停滞[2]。 Animal Model: SCID beige mice bearing Colo205 cells[2] Dosage: 20 mg/kg Administration: i.p.; once weekly; for 6 weeks Result: Showed tumor growth inhibition.
References	[1]. Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. [2]. Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92.

No Any Chemical & Physical Properties

Vanucizumab

Use of Vanucizumab

Names

Vanucizumab Biological Activity

Chemical & Physical Properties